Health Canada
list identifies select companies that can supply psilocybin to
approved applicants through the Special Access Program for patient
treatment
VANCOUVER, BC, Jan. 27, 2022 /CNW/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental
healthcare company advancing innovative treatments and safe,
evidence-based psychedelic-assisted therapies, is pleased to
announce that its research facility, Numinus Bioscience, has been
included on Health Canada's list of federally licensed psilocybin
producers.
This list is available by request to those seeking access to
psilocybin through the Special Access Program (SAP), and clinical
researchers. The SAP is a federal program that allows healthcare
professionals to apply for access to non-marketed medications that
have not yet been approved for sale, when such medications show
clinical evidence of safety and efficacy and are intended to treat
patients with severe or life-threatening illness. Earlier this
month, Health Canada added certain psychedelic compounds to the SAP
that were previously available only through clinical trials.
"Through our inclusion, we look forward to collaborating with
healthcare providers and other groups to ensure people in need
receive efficacious treatments," said Sharan Sidhu, Science Officer and General
Manager, Numinus Bioscience.
At this time, Numinus Bioscience is prepared to supply
psilocybin in whole mushroom form, through three packaged doses
equivalent to 10, 15 and 25mg of psilocybin. These doses are
produced under Good Agricultural and Collection Practices and
tested for potency and impurities to support patient safety and
practitioner confidence. With sufficient clinical data, Numinus may
also make available other products that are currently being
developed in its IP pipeline, should those meet the standards
identified by Health Canada. With its Dealer's License and research
facility, Numinus Bioscience is permitted to conduct several
activities in addition to the production of psilocybin, including
assembly, sale, export, analytical testing and R&D of ketamine,
LSD and MDMA.
"Numinus is glad to see Health Canada committing to broadened
mental healthcare access, starting with those in most need," said
Payton Nyquvest, CEO and Founder,
Numinus. "As clinical evidence grows, we look forward to making
more treatments available and further advancing the development of
psychedelic therapies and mental health innovations."
About Numinus
Numinus Wellness helps people to heal
and be well through the development and delivery of innovative
mental health care and access to safe, evidence-based
psychedelic-assisted therapies. The Numinus model – including
psychedelic production, research and clinic care – is at the
forefront of a transformation aimed at healing rather than managing
symptoms for depression, anxiety, trauma, pain and substance use.
At Numinus, we are leading the integration of psychedelic-assisted
therapies into mainstream clinical practice and building the
foundation for a healthier society.
Learn more at numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-Looking Statements
Statements and other
information contained in this press release about anticipated
future events constitute forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as "seek", "anticipate", "believe", "plan",
"estimate", "expect" and "intend" and statements that an event
"may", "will", "should", "could" or "might" occur or other similar
expressions. Forward-looking statements are subject to risks and
uncertainties and other factors that could cause actual results to
differ materially from those contained in the forward-looking
statements. Forward-looking statements are based on estimates and
opinions of management at the date the statements are made. The
Company does not undertake any obligation to update forward-looking
statements even if circumstances or management's estimates or
opinions should change except as required by applicable laws.
Investors should not place undue reliance on forward-looking
statements.
View original
content:https://www.prnewswire.com/news-releases/numinus-identified-as-a-licensed-psilocybin-supplier-by-health-canada-301469357.html
SOURCE Numinus Wellness Inc.
